CALGARY, AB, May 20, 2025 /PRNewswire/ - Enbridge Inc. (TSX: ENB) (NYSE: ENB) (Enbridge) announced today that none of its outstanding Cumulative Redeemable Preference Shares, Series 13 (Series 13 Shares) will be converted into Cumulative Redeemable Preference Shares, Series 14 (Series 14 Shares) on June 1, 2025.After taking into account all conversion notices received from holders of its outstanding Series 13 Shares by the May 20, 2025 deadline for the conversion of the Series 13 Shares into Series 14 Share ...

Palo Alto Networks (PANW) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.90%. A quarter ago, it was expected that this security software maker would post earnings of $0.78 per share when it actually produced earnings of $0.81, delivering a surprise of 3.85%.Over the last four quart ...

Core Viewpoint - A class action lawsuit is pending against Rocket Companies, alleging securities fraud and unlawful business practices by the company and its executives [2][3]. Summary by Relevant Sections Class Action Details - The lawsuit is on behalf of all individuals and entities that purchased Rocket Companies securities between March 29, 2021, and April 1, 2021, seeking damages for violations of federal securities laws [2]. - Investors have until July 8, 2025, to request appointment as Lead Plaintiff if they acquired Rocket securities during the specified Class Period [3]. Allegations Against Rocket Companies - The complaint alleges that Rocket's gain on sale margins were contracting at the highest rate in two years due to increased competition among mortgage lenders and a shift towards lower-margin operations [3]. - It is claimed that Rocket was engaged in a price war in the wholesale market, further compressing margins [3]. - The adverse trends were reportedly accelerating, with expectations that gain on sale margins would plummet by at least 140 basis points in the first half of 2021 [3]. - The favorable market conditions that previously allowed Rocket to achieve high gain on sale margins had disappeared, returning to levels not seen since Q1 2019 [3]. - The company's gain-on-sale margins had fallen materially below recent historical averages, contradicting prior positive statements made by the defendants about the company's operations and prospects [3].

Group 1 - The offering resulted in aggregate gross proceeds of approximately USD 557.0 million, with EQT receiving around USD 239.6 million from the sale of shares [1] - EQT sold approximately 6.2 million shares in the offering and now holds approximately 32.6 million shares of Waystar Holding Corp [1] - The offering included the full exercise of the underwriters' option to purchase approximately 1.9 million additional shares of common stock [1] Group 2 - The offering was managed by J.P. Morgan, Goldman Sachs & Co. LLC, and Barclays as joint book-running managers [1] - The completion of the offering for the base shares occurred on May 16, 2025, while the additional shares were completed on May 20, 2025 [1] - Waystar Holding Corp. did not sell any shares in the offering and did not receive any proceeds from the sale [1]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Fulgent Genetics, Inc. and its officers or directors [1][2] Group 1: Investigation Details - Pomerantz LLP is representing investors of Fulgent Genetics, Inc. in an investigation regarding claims of securities fraud [1] - The investigation follows a civil investigative demand received by Fulgent from the U.S. Department of Justice concerning potential false claims under the Uninsured Program [2] - Following the disclosure of the civil investigative demand, Fulgent's stock price decreased by $0.41 per share, or 2.61%, closing at $15.28 per share on March 3, 2025 [2] Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in the field [3] - The firm has a track record of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - UroGen Pharma Ltd. is under investigation for potential securities fraud and unlawful business practices, following concerns raised by the FDA regarding the clinical trial design of its bladder cancer drug UGN-102 [1][2]. Group 1: Investigation and Legal Actions - Pomerantz LLP is investigating claims on behalf of UroGen investors, focusing on possible securities fraud or other unlawful practices by the company and its officers [1]. - The investigation is prompted by the FDA's concerns regarding the Envision trial for UGN-102, which lacked a concurrent control arm, making the trial's primary endpoints difficult to interpret [2]. Group 2: FDA Concerns and Market Reaction - The FDA's briefing document indicated that it had recommended a randomized trial design to UroGen multiple times to address concerns about the trial's validity [2]. - Following the news of the FDA's concerns, UroGen's stock price dropped by $2.54 per share, representing a decline of 25.79%, closing at $7.31 per share on May 16, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices by Travere Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 15, 2025, Travere announced that the FDA plans to hold an advisory committee meeting regarding its supplemental New Drug Application for FILSPARI, aimed at treating focal segmental glomerulosclerosis [2] - Following the FDA announcement, Travere's stock price dropped by $4.35, or 20.57%, closing at $16.80 per share on May 16, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3]

Company Overview - Apogee Enterprises, Inc. (NASDAQ: APOG) has been facing significant challenges recently, particularly in its revenue, profits, and cash flow [1] Industry Insights - The focus of Crude Value Insights is on oil and natural gas, emphasizing cash flow and the companies that generate it, which leads to value and growth prospects [1]

Core Viewpoint - Hometown Financial Group has announced a definitive merger agreement to acquire CFSB Bancorp and its subsidiary Colonial Federal Savings Bank, enhancing its market presence in eastern Massachusetts and creating a larger banking entity with significant assets and branch locations [1][2][4]. Merger Details - The merger agreement has been unanimously approved by the boards of directors of both companies, with CFSB shareholders set to receive $14.25 in cash per share, valuing the transaction at approximately $44 million [2]. - The merger is expected to close in the fourth quarter of 2025, pending regulatory approvals and shareholder consent [2]. Post-Merger Structure - Following the merger, Colonial Federal Savings Bank will merge into North Shore Bank, resulting in a combined bank with $3.3 billion in assets and 29 retail locations across Massachusetts and southern New Hampshire [3]. - Hometown Financial Group will have consolidated assets nearing $6.9 billion and a total of 56 branch offices after the merger [4]. Strategic Goals - The merger aims to enhance customer service and expand market reach, with Hometown Financial Group emphasizing its commitment to local markets and personalized financial solutions [5][6]. - The transaction marks the eighth strategic merger for Hometown Financial Group in the last decade, indicating a consistent growth strategy [7]. Company Background - Hometown Financial Group is a multibank mutual holding company with $6.6 billion in assets, operating several banks including bankESB, bankHometown, and North Shore Bank [13]. - CFSB Bancorp, with total assets of $366 million as of March 31, 2025, has been serving the banking needs of its customers since 1889 [16].

Apple reportedly plans to introduce tools that will let third-party developers write software using the large language models that power Apple Intelligence.The company is set to announce the software development kit and other resources that will allow this capability on June 9 at its Worldwide Developers Conference, Bloomberg reported Tuesday (May 20), citing unnamed sources.Apple did not immediately reply to PYMNTS’ request for comment.By expanding its AI technology to developers, the company hopes to enco ...